Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2849883rdf:typepubmed:Citationlld:pubmed
pubmed-article:2849883lifeskim:mentionsumls-concept:C0019169lld:lifeskim
pubmed-article:2849883lifeskim:mentionsumls-concept:C0019163lld:lifeskim
pubmed-article:2849883lifeskim:mentionsumls-concept:C0019165lld:lifeskim
pubmed-article:2849883lifeskim:mentionsumls-concept:C0019166lld:lifeskim
pubmed-article:2849883lifeskim:mentionsumls-concept:C0037140lld:lifeskim
pubmed-article:2849883lifeskim:mentionsumls-concept:C2239176lld:lifeskim
pubmed-article:2849883lifeskim:mentionsumls-concept:C0012854lld:lifeskim
pubmed-article:2849883lifeskim:mentionsumls-concept:C2754997lld:lifeskim
pubmed-article:2849883lifeskim:mentionsumls-concept:C0019164lld:lifeskim
pubmed-article:2849883lifeskim:mentionsumls-concept:C0019167lld:lifeskim
pubmed-article:2849883lifeskim:mentionsumls-concept:C1707520lld:lifeskim
pubmed-article:2849883pubmed:issue6lld:pubmed
pubmed-article:2849883pubmed:dateCreated1989-2-7lld:pubmed
pubmed-article:2849883pubmed:abstractTextSera from 102 black patients with primary hepatocellular carcinoma (PHC) and hepatitis B surface antigenemia were tested for immunoglobulin M antibody against hepatitis B core (IgM anti-HBc), hepatitis B e antigen (HBeAg), and hepatitis B viral (HBV) DNA. Their prevalences were compared to those of a control group of 124 age and sex matched black HBV carriers without tumor. IgM anti-HBc was present in 68.6%, HBeAg in 32.3%, and HBV-DNA in 26.7% of the patients. In the control population, IgM anti-HBc was present in 45%, HBeAg was detected in 3.2%, and HBV-DNA in 25.8%. We conclude that IgM anti-HBc is present appreciably more often than either HBeAg or HBV-DNA in patients with PHC. HBeAg or IgM anti-HBc in serum of HBsAg positive carriers may predict an added risk of PHC development in South African blacks.lld:pubmed
pubmed-article:2849883pubmed:languageenglld:pubmed
pubmed-article:2849883pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2849883pubmed:citationSubsetAIMlld:pubmed
pubmed-article:2849883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2849883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2849883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2849883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2849883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2849883pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2849883pubmed:statusMEDLINElld:pubmed
pubmed-article:2849883pubmed:monthDeclld:pubmed
pubmed-article:2849883pubmed:issn0002-9637lld:pubmed
pubmed-article:2849883pubmed:authorpubmed-author:SonoMMlld:pubmed
pubmed-article:2849883pubmed:authorpubmed-author:KewM CMClld:pubmed
pubmed-article:2849883pubmed:authorpubmed-author:DusheikoG MGMlld:pubmed
pubmed-article:2849883pubmed:authorpubmed-author:SjogrenM HMHlld:pubmed
pubmed-article:2849883pubmed:issnTypePrintlld:pubmed
pubmed-article:2849883pubmed:volume39lld:pubmed
pubmed-article:2849883pubmed:ownerNLMlld:pubmed
pubmed-article:2849883pubmed:authorsCompleteYlld:pubmed
pubmed-article:2849883pubmed:pagination582-5lld:pubmed
pubmed-article:2849883pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:meshHeadingpubmed-meshheading:2849883-...lld:pubmed
pubmed-article:2849883pubmed:year1988lld:pubmed
pubmed-article:2849883pubmed:articleTitleHepatitis B virus infection and hepatocellular carcinoma: correlation between IgM antibody to hepatitis B core antigen, hepatitis B e antigen, and hepatitis B DNA.lld:pubmed
pubmed-article:2849883pubmed:affiliationDepartment of Virus Diseases, Walter Reed Army Institute of Research, Washington, DC.lld:pubmed
pubmed-article:2849883pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2849883pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:2849883pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed